Table 1

Patient demographic data and baseline characteristics (intention-to-treat population)

CZP 400 mg (n=89)
Age, mean±SD, years30.2±9.9
BMI, mean±SD, kg/m2 22.1±3.6
Males, n (%)30 (34)
CRP, mg/l
 Geometric mean (CV)19 (1.4)
Disease duration, years
Number of resections, n (%)
 071 (80)
 111 (12)
 25 (6)
 32 (2)
Prior anti-TNF therapy, n (%)2 (2)
At least one concomitant medication potentially influencing CD, % patients79
 5-Aminosalicylic acid22
  • BMI, body mass index; CD, Chron's disease; CDAI, Crohn's Disease Activity Index; CDEIS, Crohn's Disease Endoscopic Index of Severity; CRP, C reactive protein; CV, coefficient of variation; CZP, certolizumab pegol; TNF, tumour necrosis factor.